4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether 4SC-201 alone or in combination with
Sorafenib is effective and safe in the treatment of hepatocellular carcinoma in patients
refractory to Sorafenib monotherapy.